The role of hematopoietic SCT in adult Burkitt lymphoma

Ahmed, Suhaib; Sureda, Anna; Aljurf, Mahmoud

doi:10.1038/bmt.2012.129

Cited by 6 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective analysis covering nine patients with r/r BL after for the success of a potential consolidating ASCT, which represents the only therapeutic option with curative potential in patients with r/r BL [9]. Therefore, the CR induced by R-DHAP treatment paved the way for adopting a potentially curative approach in this young woman reported here.…”

Section: Case Presentationmentioning

confidence: 88%

“…Against the backdrop of the unusually swift response to R‐DHAP reported in the present case report, we believe that platinum‐based aggressive chemotherapy should not be dismissed as salvage therapy in patients with r/r BL. More importantly, achieving a second CR after relapse constitutes a crucial prerequisite for the success of a potential consolidating ASCT, which represents the only therapeutic option with curative potential in patients with r/r BL [ 9 ]. Therefore, the CR induced by R‐DHAP treatment paved the way for adopting a potentially curative approach in this young woman reported here.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Unusually swift response of relapsed Burkitt leukemia to R‐DHAP

Harrer

Denk

Keil

et al. 2022

eJHaem

View full text Add to dashboard Cite

Burkitt leukemia (BL) represents a highly aggressive lymphoma characterized by proliferation rates of around 100%, and a frequent spread into the central nervous system.If standard frontline chemotherapy fails, the prognosis is usually dismal, and reports on successful effective salvage therapy strategies for patients with relapsed/refractory BL are scant. Here, we report on a 40-year-old female patient who suffered an early relapse of BL three months after the completion of frontline chemoimmunotherapy.Strikingly, after only one cycle of R-DHAP chemotherapy, the patient showed CR of BL enabling swift transition to a consolidating allogeneic stem cell transplantation.A 40-year-old previously healthy woman presented to the hospital with fatigue and incessant epistaxis, and a diagnosis of BL was made upon histological examination of a bone marrow biopsy. Treatment was initiated according to the GMALL 2002 B-NHL/ALL protocol, which could induce complete molecular remission. Nevertheless, three months after chemotherapy, the patient exhibited BL relapse in the bone marrow, and on Fluorodeoxyglucose (FDG)-PET-imaging. The relapse therapy was started with R-DHAP, and after only one cycle, the patient once again entered complete remission (CR) paving the way for allogeneic stem cell transplantation. Unfortunately, the patient again relapsed five months after transplantation prompting salvage therapy with R-DHAC and the execution of the second stem cell transplantation. However, one month after the second transplantation the patient presented with chemorefractory meningeosis leukemia resulting in the initiation of palliative care treatment. In summary, we report on rapid CR of relapsed BL after a single cycle of rituximab-DHAP.Given a paucity of clinical trials on the treatment of patients with r/r BL, we intend to highlight the potential efficacy of rituximab-DHAP as salvage therapy in those patients.

show abstract

Section: Case Presentationmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Unusually swift response of relapsed Burkitt leukemia to R‐DHAP

Harrer

Denk

Keil

et al. 2022

eJHaem

View full text Add to dashboard Cite

show abstract

“…A complete remission (CR) of the disease for a year following treatment may be an indication of a comprehensive cure, thus the evaluation by the imaging modalities may be discontinued from the second year [1]. A complete blood count (CBC) and the cognitive function assessment may be accomplished to exclude the delayed effects of drug toxicity [11]. The disease may re-occur in the midst of the first year of treatment.…”

Section: Therapeutic Re-assessmentmentioning

confidence: 99%

“…Cycles of chemotherapy may be briefly interrupted. The patients lacking human immune deficiency virus (HIV-) infection may be managed by dose adjusted etoposide, prednisone, vincristine, cyclophophamide and doxorubicin with rituximab ( DA-EPOCH R) [11,12]. Individuals with the viral infection (HIV+) may adopt the short cycle etoposide, prednisone, vincristine, cyclophophamide and doxorubicin with riuiximab (SC-EPOCH RR) [11].…”

Section: Dictums Of Therapymentioning

confidence: 99%